Xeolas celebrates grand opening of major Dublin pharmaceutical hub
The Irish-owned pharmaceutical firm has officially unveiled a sprawling, modernised facility in Baldoyle to bolster its medicine manufacturing capabilities. This strategic expansion marks a significant milestone for the company as it continues to scale its international operations.
Xeolas Pharmaceuticals has marked a triumphant new chapter for the Irish life sciences sector with the official unveiling of its expansive 158,000 square foot facility in Baldoyle, Dublin. By consolidating research, development, and advanced manufacturing under one roof, the company has significantly enhanced its capacity to produce patient-centric medicines that address critical, unmet health needs across global markets.
Established in 2007 by CEO Damien Flynn, the firm has grown to support a workforce of over 100 professionals while maintaining a presence in 21 countries. The new site serves as a vital engine for the company’s ambitious pipeline, which currently includes more than 25 products in various stages of development. During the opening, Flynn emphasised that this infrastructure investment is a testament to the team’s scientific expertise and their unwavering commitment to delivering smarter, more effective treatment options for patients everywhere.
Industry leaders have welcomed the development as a boost to Ireland’s reputation as a centre of excellence for pharmaceutical innovation. Leo McAdams of Enterprise Ireland commended the company’s trajectory, noting that supporting ambitious Irish firms to scale globally remains a core priority. For those seeking further information regarding the company’s operations or upcoming projects, details are available on the official website, with media enquiries directed to Maeve Governey.